Insider Ownership: 13%

Earnings Growth Forecast: 78.9% p.a.

ESR Group's revenue is forecast to grow at 16.4% per year, outpacing the Hong Kong market's 7.4%. Despite an expected net loss of US$210 million for H1 2024 due to non-cash asset revaluations and a lack of promote fee income, earnings are projected to grow annually by 78.86%. Recent leadership changes include Jeffrey Perlman stepping down as chairman, with Brett Krause appointed interim chairman, bringing extensive experience in banking and investment management.

• Unlock comprehensive insights into our analysis of ESR Group stock in this growth report.

• The analysis detailed in our ESR Group valuation report hints at an inflated share price compared to its estimated value.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc., a biopharmaceutical company with a market cap of HK$48.23 billion, researches, develops, manufactures, and commercializes antibody drugs.

Operations: Akeso's revenue primarily stems from the research, development, production, and sale of biopharmaceutical products, amounting to CN￥1.87 billion.

Insider Ownership: 20.5%

Earnings Growth Forecast: 54.9% p.a.

Akeso, a growth company with substantial insider ownership, is forecast to achieve high revenue growth of 32.8% per year and become profitable within three years. Despite recent earnings showing a net loss of CNY 238.59 million for H1 2024, the company continues to advance its innovative drug pipeline. Key developments include priority review for ivonescimab's new indication and positive interim results from Phase III trials, underscoring significant clinical value in oncology treatments.

• Click to explore a detailed breakdown of our findings in Akeso's earnings growth report.

• Our comprehensive valuation report raises the possibility that Akeso is priced higher than what may be justified by its financials.

Key Takeaways

• Navigate through the entire inventory of 47 Fast Growing SEHK Companies With High Insider Ownership here.

• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1211 SEHK:1821 and SEHK:9926.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]